[Pragmatic approach to treatments in multiple sclerosis].
Vermersch
P
P
Pôle de neurologie et EA2686, Université Lille-Nord de France, Hôpital Roger Salengro, Lille. pvermersch@chru-lille.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006233:Persons with Disabilities; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D039441:Integrin alpha4 / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology / Q000628:therapy; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D039441:Integrin alpha4; D016899:Interferon-beta